Two conjugates of anticancer drug doxorubicin (Dox) covalently bound by the hydrolytically degradable hydrazone bond to the polymer carrier based on water-soluble N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers were synthesized and their properties were compared, namely their behavior in vivo. The polymer carriers differed in dispersity due to different methods of synthesis; the carrier with relatively high dispersity (HD) was prepared by free radical polymerization (Mw=29,900 g/mol, D=1.75) and the carrier with low dispersity (LD) by controlled radical polymerization (Mw=30,000 g/mol, D=1.13). Both polymer-Dox conjugates showed prolonged blood circulation and tumor accumulation of the drug in comparison with the free drug; e.g. the tumor-to-blood ratio for the polymer-bound Dox was 3-5 times higher. The LD polymer-Dox conjugate exhibited moderately higher tumor accumulation than the HD one at a dose of 1x15 mg Dox (eq.)/kg. Also, their anti-tumor activity did not differ when injected at this dose. However, the increase of the dose to 1x25 mg Dox (eq.)/kg resulted in the enhanced therapeutic activity of the conjugates, especially of the LD one with 100% of long-term survivals. The dispersity of polymer drug carriers influenced the tumor accumulation rate, which affected the overall anti-cancer activity of polymer-drug conjugates.

Institute of Macromolecular Chemistry Academy of Sciences of the Czech Republic Prague Czech Republic

Institute of Microbiology Academy of Sciences of the Czech Republic Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16019734

003      

CZ-PrNML

005      

20170418094546.0

007      

ta

008      

160721s2015 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.33549/physiolres.933137 $2 doi

035    __

$a (PubMed)26447594

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Chytil, Petr $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic $7 _AN032430

245    14

$a The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization / $c P. Chytil, M. Šírová, E. Koziolová, K. Ulbrich, B. Říhová, T. Etrych

520    9_

$a Two conjugates of anticancer drug doxorubicin (Dox) covalently bound by the hydrolytically degradable hydrazone bond to the polymer carrier based on water-soluble N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers were synthesized and their properties were compared, namely their behavior in vivo. The polymer carriers differed in dispersity due to different methods of synthesis; the carrier with relatively high dispersity (HD) was prepared by free radical polymerization (Mw=29,900 g/mol, D=1.75) and the carrier with low dispersity (LD) by controlled radical polymerization (Mw=30,000 g/mol, D=1.13). Both polymer-Dox conjugates showed prolonged blood circulation and tumor accumulation of the drug in comparison with the free drug; e.g. the tumor-to-blood ratio for the polymer-bound Dox was 3-5 times higher. The LD polymer-Dox conjugate exhibited moderately higher tumor accumulation than the HD one at a dose of 1x15 mg Dox (eq.)/kg. Also, their anti-tumor activity did not differ when injected at this dose. However, the increase of the dose to 1x25 mg Dox (eq.)/kg resulted in the enhanced therapeutic activity of the conjugates, especially of the LD one with 100% of long-term survivals. The dispersity of polymer drug carriers influenced the tumor accumulation rate, which affected the overall anti-cancer activity of polymer-drug conjugates.

650    _2

$a zvířata $7 D000818

650    _2

$a antibiotika antitumorózní $x chemie $x farmakokinetika $x farmakologie $7 D000903

650    _2

$a léky s prodlouženým účinkem $7 D003692

650    _2

$a doxorubicin $x chemie $x farmakokinetika $x farmakologie $7 D004317

650    _2

$a nosiče léků $7 D004337

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a volné radikály $x chemie $7 D005609

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a methakryláty $x chemie $7 D008689

650    _2

$a myši $7 D051379

650    _2

$a myši inbrední C57BL $7 D008810

650    _2

$a experimentální nádory $x farmakoterapie $x metabolismus $x patologie $7 D009374

650    _2

$a polymery $x chemická syntéza $7 D011108

650    _2

$a analýza přežití $7 D016019

650    _2

$a tkáňová distribuce $7 D014018

650    _2

$a xenogenní modely - testy antitumorózní aktivity $7 D023041

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Šírová, Milada $7 xx0127158 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

700    1_

$a Koziolová, Eva $7 _AN081673 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

700    1_

$a Ulbrich, Karel, $d 1947- $7 jo2004259877 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

700    1_

$a Říhová, Blanka, $d 1942- $7 jo20000073671 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

700    1_

$a Etrych, Tomáš $7 xx0068504 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

773    0_

$w MED00003824 $t Physiological research Academia Scientiarum Bohemoslovaca $x 1802-9973 $g Roč. 64, Suppl. 1 (2015), s. S41-S49

773    0_

$t Recent advances in BIOCEV research projects $g (2015), s. S41-S49 $w MED00191407

856    41

$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu

910    __

$a ABA008 $b A 4120 $c 266 $y 4 $z 0

990    __

$a 20160721 $b ABA008

991    __

$a 20170418094854 $b ABA008

999    __

$a ok $b bmc $g 1156631 $s 944262

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 64 $c Suppl. 1 $d S41-S49 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824

BMC    __

$a 2015 $d S41-S49 $m Recent advances in BIOCEV research projects $x MED00191407

LZP    __

$b NLK118 $a Pubmed-20160721